What is CytomX Therapeutics's financing cash flow?

CytomX Therapeutics (CTMX) reported financing cash flow of $234.49M in Q1 2026.

What is the long-term trend for CytomX Therapeutics's financing cash flow?

Over 4 years (2021 to 2025), CytomX Therapeutics's financing cash flow has grown at a 0.1% compound annual growth rate (CAGR), from $110.21M to $110.45M.

What does financing cash flow mean?

Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

CytomX Therapeutics CTMX Financing Cash Flow

Financing Cash Flow at other companies

PfizerPFE

-$2.86B+45.4%

AmgenAMGN

$1.44B+135%

Janux TherapeuticsJANX

$3.55M+540%

Allogene TherapeuticsALLO

$21.12M+51.0%

Vor BiopharmaVOR

$74.87M+12,455%

Design Therapeutics, Inc.DSGN

$19.93M+86,570%

Other financials

Income statement

See full

Revenue$10.3M-79.9%

Operating income-$19.7M-187%

Net income-$18.2M-178%

EPS (diluted)-$0.10-137%

Balance sheet

See full

Cash & equivalents$28.8M-39.4%

Total debt$2.9M-65.0%

Total equity$319.9M+1,177%

Total assets$359.4M+265%

Cash flow

See full

Operating cash flow-$25.5M-21.4%

CapEx--100%

Free cash flow-$25.5M-20.7%

Valuation

See full

Market cap$711.89M+94.8%

Enterprise value$685.92M+110%

P/S20×+17.6×

Profitability

See full

Operating margin-181.9%-206pp

Net margin-166.4%-195pp

FCF margin-225.6%-334pp

Returns & leverage

See full

Return on equity-34.3%—

Debt / equity0×-0.3×

Current ratio10.4×+8.7×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CytomX Therapeutics's financing cash flow?: CytomX Therapeutics (CTMX) reported financing cash flow of $234.49M in Q1 2026.
What is the long-term trend for CytomX Therapeutics's financing cash flow?: Over 4 years (2021 to 2025), CytomX Therapeutics's financing cash flow has grown at a 0.1% compound annual growth rate (CAGR), from $110.21M to $110.45M.
What does financing cash flow mean?: Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.